Form 4: Oric Pharmaceuticals CEO Exercises Stock Options and Sells Shares to Cover Taxes

Oric Pharmaceuticals CEO, Jacob Chacko, exercised stock options and sold shares to cover tax obligations, while also acquiring shares through stock plan.

Summary

• Oric Pharmaceuticals CEO, Jacob Chacko, engaged in multiple transactions involving the company's stock.
• On December 15, 2024, Mr. Chacko acquired 67,000 shares of common stock through the exercise of restricted stock units (RSUs).
• These RSUs were part of awards that vest over time, with different tranches vesting on December 15th of 2022, 2023, 2024, 2025 and 2026.
• On December 16, 2024, Mr. Chacko sold 24,660 shares at a weighted average price of $8.2812 per share.
• The sale was to cover tax withholding obligations related to the vesting of the RSUs and was not a discretionary sale.
• Following these transactions, Mr. Chacko beneficially owns 778,648 shares of Oric Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions, which are neither particularly positive nor negative. The sale of shares is for tax purposes, which is a common practice.

Positives

• The CEO's acquisition of 67,000 shares through RSU vesting indicates a continued alignment with the company's long-term success.
• The vesting of RSUs is a standard practice for executive compensation and incentivizes performance.

Negatives

• The sale of 24,660 shares, even for tax purposes, could be perceived negatively by some investors, although it is a common practice.
• The sale of shares by the CEO, even for tax purposes, may create a short term downward pressure on the share price.

Risks

• Executive stock sales, even for tax purposes, can sometimes be misinterpreted by the market and lead to short-term price volatility.
• The timing of the sale could be seen as opportunistic, even though it was to cover tax obligations.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives engage in stock transactions. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sale of shares to cover taxes is a common practice among publicly traded companies, particularly in the biotech sector.
• Many biotech companies use equity-based compensation to attract and retain talent, and these transactions are a normal part of that process.
• Comparable companies such as Xencor, Inc. and Arcus Biosciences, Inc. also regularly report similar transactions by their executives.

Stakeholder Impact

• Shareholders may have a neutral reaction to this filing as it is a routine transaction.
• Employees may see this as a normal part of the company's compensation structure.

Key Dates

Keywords

stock options, insider trading, executive compensation, restricted stock units, share sale, ORIC, Jacob Chacko